Cancer Research Horizons focuses its investments on early-stage oncology ventures, encompassing therapeutics, diagnostics, medical devices, and data-driven/AI solutions. Their strategy prioritizes patient impact by taking calculated risks on novel ideas that address unmet needs in cancer, providing crucial early-stage capital and venture creation support.
75% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (3 deals in the last 12 months). Their most common stage is series-a (50% of deals). Average disclosed round size is $34.8M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$38.1M
Top Stage
Series A
Last 12 Mo
3
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Infinitopes | Seed | $35.1M | Jan 2026 |
 Trogenix | Series A | $80M | Oct 2025 |
 AiM Medical Robotics | Series A | $8.1M | Sep 2025 |
| Infinitopes | Seed | $16M | Apr 2024 |
Top Co-Investors
IQ Capital2 shared
Octopus Ventures2 shared
Manta Ray Ventures2 shared
Sontag Innovation Fund1 shared
New York Angels1 shared
Keiretsu Forum1 shared
Macmillan Cancer Support1 shared
Kindred Ventures1 shared
Martlet1 shared
4BIO Capital1 shared
Brain Tumor Investment Fund1 shared
Eli Lilly and Company1 shared
LongeVC1 shared
Calculus Capital1 shared
Last updated: 9 April 2026